AmyElizabethDezernMD

Oncology • Baltimore, MD

Hematologic Oncology

Assistant Professor of Oncology, Assistant Professor of Medicine, Johns Hopkins University School of Medicine

Join to view full profile

Dr. Dezern is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dezern's full profile

Already have an account?

Office
401 North Broadway Street
Weinberg BLDG
Baltimore, MD 21287
Phone+1 410-955-8964

Fax+1 410-367-2194

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2008 - 2012
Johns Hopkins UniversityResidency, Internal Medicine, 2005 - 2008
Johns Hopkins University School of MedicineClass of 2005

Certifications & Licensure

MD State Medical License 2008 - 2026
VA State Medical License 2021 - 2026
PA State Medical License 2021 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia Start of enrollment: 2009 Jul 01
Terminated
Phase 2
Bone Marrow Transplant Trial for Patients With Refractory Severe Aplastic Anemia Start of enrollment: 2011 Jun 01
Terminated
Phase 2
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Red Cell Transfusion Goals in Patients With Acute Leukemias Start of enrollment: 2014 Apr 01
Completed
Phase 1
Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia Start of enrollment: 2014 Aug 01
Completed
Phase 2
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Start of enrollment: 2015 Dec 01
Completed
Phase 2
Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients Start of enrollment: 2021 Nov 09
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome Start of enrollment: 2018 Jan 17
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies.
Piyanuch Kongtim, Pongthep Vittayawacharin, Jun Zou, Samer Srour, Brian Shaffer
Transplantation and Cellular Therapy. 2024-12-01
Therapy-related myelodysplastic syndromes and acute myeloid leukemia.
Sangeetha Venugopal, Amy E DeZern
Seminars in Hematology. 2024-12-01
Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and ...
Raheel Iftikhar, Zachariah DeFilipp, Amy E DeZern, Michael A Pulsipher, Nelli Bejanyan
Transplantation and Cellular Therapy. 2024-12-01

Abstracts/Posters

Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (_6...
Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML)
Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...
Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML
Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis
Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study
Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Shortened Immunosuppression Following Peripheral Blood (PB) Haploidentical (haplo) Transplantation with Post-Transplant Cyclophosphamide (PTCy) Is Associated with Tole...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
ASH Networking Reception for Women in Hematology
60th American Society of Hematology Annual Meeting - 12/3/2018
The Molecular Maelstrom of Myelodysplastic Syndromes (MDS)
60th American Society of Hematology Annual Meeting - 12/2/2018
The Molecular Maelstrom of Myelodysplastic Syndromes (MDS)
60th American Society of Hematology Annual Meeting - 12/1/2018
17th Update in Hematologic Malignancies
The Johns Hopkins University School of Medicine, Baltimore, Maryland - 4/26/2013
Join now to see all

Press Mentions

'Dietary' Vulnerability Found in Cancer Cells with Mutated SpliceosomesOctober 3rd, 2019
ASH Presents Honorific Awards, Immunotherapy Researchers Receive Nobel Prize in Medicine, and MoreDecember 1st, 2018